Pipeline

PIPELINE

Optimized and Genetically-Engineered TIL Therapies

Our optimized TIL therapies leverage our platform for TIL manufacturing, which has been designed to improve the scalability, logistics, and accessibility of TIL therapy. We are also developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.

Optimized TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3
ITIL-168 (Delta-1) Melanoma
ITIL-168 + Pembro (Delta-2) NSCLC
ITIL-168 + Pembro (Delta-2) HNSCC
ITIL-168 + Pembro (Delta-2) Cervical Cancer
CoStAR-TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3
ITIL-306 NSCLC, Ovarian, RCC
Multiple Undisclosed

NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; RCC: renal cell carcinoma; Pembro: pembrolizumab